Norwegian (Bokmål) English 

Årsrapport

Norwegian (Bokmål) English 

IRIS Commercialisation

There has been a strong equity growth in the portfolio of commercialisation companies in recent years. This growth continued in 2014. The current value of associated companies increased from MNOK 21 in 2013 to MNOK 59 in 2014. Rhe merger of BioProtein AS with US Calysta Inc. contributed to this in particular.

The successful installation of the system for partial automation of drilling operations (Drilltronics™) presents new opportunities for the company Sekal AS. Efforts to commercialize some of the technology from the company Hole in One Producer AS has secured substantial support from DEMO2000, a program run by the Research Council of Norway.
iris17